We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04602000
Recruitment Status : Completed
First Posted : October 26, 2020
Results First Posted : July 20, 2022
Last Update Posted : July 20, 2022
Sponsor:
Information provided by (Responsible Party):
Celltrion

Brief Summary:
This was a Phase 2/3 study to assess the efficacy about therapeutic effect of CT-P59 to the mild to moderate SARS-CoV-2 infected patients and the safety during after study drug injection.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Infection Biological: CT-P59 Biological: Placebo Phase 2 Phase 3

Detailed Description:
CT-P59 is a human monoclonal antibody targeted against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a treatment for SARS-CoV-2 infection, which is manufactured by recombinant deoxyribonucleic acid technology in a Chinese hamster ovary mammalian cell line. This Phase 2/3, randomized, parallel-group, placebo-controlled, double-blind study was designed to evaluate the safety, tolerability, and therapeutic potential of CT-P59 in outpatients with mild to moderate SARS-CoV-2 infection, not requiring supplemental oxygen therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1642 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With SARS-CoV-2 Infection
Actual Study Start Date : October 5, 2020
Actual Primary Completion Date : May 21, 2021
Actual Study Completion Date : October 20, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CT-P59 40 mg/kg group (Part 1)
CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
Biological: CT-P59
CT-P59 (40 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
Other Name: regdanvimab

Experimental: CT-P59 80 mg/kg group (Part 1)
CT-P59 (regdanvimab), 80 mg/kg by IV infusion once
Biological: CT-P59
CT-P59 (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)
Other Name: regdanvimab

Placebo Comparator: Placebo group (Part 1)
Placebo, matching in volume of CT-P59 80 mg/kg by IV infusion once
Biological: Placebo
Placebo (80 mg/kg) by IV infusion administered over 90 minutes, once (Part 1)

Experimental: CT-P59 40 mg/kg group (Part 2)
CT-P59 (regdanvimab), 40 mg/kg by IV infusion once
Biological: CT-P59
CT-P59 (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)
Other Name: regdanvimab

Placebo Comparator: Placebo group (Part 2)
Placebo, matching in volume of CT-P59 40 mg/kg by IV infusion once
Biological: Placebo
Placebo (40 mg/kg) by IV infusion administered over 60 minutes, once (Part 2)




Primary Outcome Measures :
  1. Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection (Part 1) [ Time Frame: Up to Day 28 ]
    To assess the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28

  2. Proportion of Patients With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1) [ Time Frame: Up to Day 14 ]
    To assess the potential therapeutic efficacy of CT-P59 as determined by proportion of negative conversion in nasopharyngeal swab specimen based on RT-qPCR up to Day 14

  3. Time to Negative Conversion in Nasopharyngeal Swab Specimen (Part 1) [ Time Frame: Up to Day 14 ]
    To evaluate the therapeutic efficacy of CT-P59 as determined by time to negative conversion by RT-qPCR up to Day 14

  4. Time to Clinical Recovery (Part 1) [ Time Frame: Up to Day 14 ]

    To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14.

    Clinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent [0], mild [1]. moderate [2], and severe [3]).

    To meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms "absent" in intensity at baseline should maintain as "absent" for at least 48 hours.


  5. Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in High-risk Patients (Part 2) [ Time Frame: Up to Day 28 ]
    To demonstrate the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28 in high-risk patients


Secondary Outcome Measures :
  1. Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in All Randomized Patients (Part 2) [ Time Frame: Up to Day 28 ]
    To demonstrate the clinically meaningful therapeutic efficacy of CT-P59 as determined by proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection up to Day 28 in all randomized patients

  2. Time to Clinical Recovery up to Day 14 in High-risk Patients (Part 2) [ Time Frame: Up to Day 14 ]

    To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14 in high-risk patients.

    Clinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent [0], mild [1]. moderate [2], and severe [3]).

    To meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms "absent" in intensity at baseline should maintain as "absent" for at least 48 hours.


  3. Time to Clinical Recovery up to Day 14 in All Randomized Patients (Part 2) [ Time Frame: Up to Day 14 ]

    To assess the potential therapeutic efficacy of CT-P59 as determined by time to clinical recovery up to Day 14 in all randomized patients.

    Clinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent [0], mild [1]. moderate [2], and severe [3]).

    To meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms "absent" in intensity at baseline should maintain as "absent" for at least 48 hours.


  4. Proportion of Patients With Hospital Admission Due to SARS-CoV-2 Infection (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  5. Proportion of Patients Requiring Supplemental Oxygen Due to SARS-CoV-2 Infection (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  6. Proportion of Patients With Mechanical Ventilation Use Due to SARS-CoV-2 Infection (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  7. Proportion of Patients Requiring Rescue Therapy Due to SARS-CoV-2 Infection (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  8. Proportion of Patients With Intensive Care Unit Transfer Due to SARS-CoV-2 Infection (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  9. Proportion of Patients With All-cause Mortality (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  10. Time to Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]
    To evaluate the additional efficacy of CT-P59

  11. Proportion of Patient With Negative Conversion in Nasopharyngeal Swab Specimen Based on RT-qPCR at Each Visit (Part 1 and Part 2) [ Time Frame: Days 3, 7, 10, 14, 21, and 28 ]
    To evaluate the additional efficacy of CT-P59

  12. Time to Clinical Recovery (Part 1 and Part 2) [ Time Frame: Up to Day 28 ]

    To evaluate the additional efficacy of CT-P59. Clinical recovery was defined as all symptoms on the SARS-CoV-2 Infection Symptom Checklist 1 being recorded as 'absent' or 'mild' in intensity for at least 48 hours. SARS-CoV-2 Infection Symptom Checklist 1 consisted of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) and the intensity of patient's self-aware for each SARS-CoV-2 infection symptom (absent [0], mild [1]. moderate [2], and severe [3]).

    To meet the clinical recovery, symptoms 'severe' or 'moderate' in intensity at baseline should be changed to 'mild' or 'absent', or symptoms 'mild' in intensity at baseline should be changed to 'absent', after the study drug administration. Symptoms "absent" in intensity at baseline should maintain as "absent" for at least 48 hours.



Other Outcome Measures:
  1. [Virology] Viral Serology for SARS-CoV-2 Antibody [ Time Frame: Days 1, 7, 14, 28, and 56 ]
    To assess the serology of SARS-CoV-2 antibody. The proportions of patients positive with IgG or IgM were summarized.

  2. [PK] Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) (Part 1) [ Time Frame: Pre-dose, end of infusion, 1, 24, 48, 96, 144, 216, 312, 648, 1320, 2136 hours after start of infusion ]
    To assess the PK of CT-P59

  3. [PK] Maximum Serum Concentration (Cmax) (Part 1) [ Time Frame: Pre-dose, end of infusion, 1, 24, 48, 96, 144, 216, 312, 648, 1320, 2136 hours after start of infusion ]
    To assess the PK of CT-P59

  4. [PK] Terminal Half-life (t1/2) (Part 1) [ Time Frame: Pre-dose, end of infusion, 1, 24, 48, 96, 144, 216, 312, 648, 1320, 2136 hours after start of infusion ]
    To assess the PK of CT-P59



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patient had to meet all of the following criteria to be randomized in this study.

  1. Patient was an adult male or female patient, aged 18 or above.
  2. Patient was diagnosed with SARS-CoV-2 infection at Screening by using the sponsor-supplied rapid SARS-CoV-2 diagnostic test or RT-PCR (reverse transcription-polymerase chain reaction).
  3. Patient with conditions meeting all of the following criteria:

    1. Oxygen saturation > 94% on room air.
    2. Not requiring supplemental oxygen.
  4. Patient who had an onset of symptom no more than 7 days prior to the study drug administration.
  5. Patient had 1 or more of the SARS-CoV-2 infection-associated symptoms within but no more than 7 days prior to the study drug administration.

Exclusion Criteria:

Patients meeting any of the following criteria were excluded from the study.

  1. Patient had current severe condition meeting one of the following:

    1. Previous or current hospitalization or requirement of hospitalization for treatment of serious SARS-CoV-2 related conditions.
    2. Respiratory distress with respiratory rate ≥30 breaths/min.
    3. Required supplemental oxygen
    4. Experienced shock
    5. Complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion.
  2. Patient had received or had a plan to receive any of the following prohibited medications or treatments:

    1. Drugs with actual or possible antiviral drugs and/or possible anti-SARS-CoV-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of SARS-CoV-2 infection prior to study drug administration
    2. Any SARS-CoV-2 human IV immunoglobulin, convalescent plasma for the treatment of SARS-CoV-2 infection prior to study drug administration
    3. Any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of SARS-CoV-2 infection prior to the study drug administration
    4. Use of medications that are contraindicated with SoC
    5. SARS-CoV-2 vaccine prior to the study drug administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04602000


Locations
Layout table for location information
Korea, Republic of
Chungnam National University Hospital
Daejeon, Jung-gu, Korea, Republic of, 35015
Sponsors and Collaborators
Celltrion
  Study Documents (Full-Text)

Documents provided by Celltrion:
Study Protocol  [PDF] April 30, 2021
Statistical Analysis Plan: Part 1  [PDF] July 22, 2021
Statistical Analysis Plan: Part 2  [PDF] December 16, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Celltrion
ClinicalTrials.gov Identifier: NCT04602000    
Other Study ID Numbers: CT-P59 3.2
2020-003369-20 ( EudraCT Number )
First Posted: October 26, 2020    Key Record Dates
Results First Posted: July 20, 2022
Last Update Posted: July 20, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Communicable Diseases
COVID-19
Disease Attributes
Pathologic Processes
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases